Details of a Researcher - Shigematsu, Naoyuki

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Ito K., Saito S., Yorozu A., Kojima S., Kikuchi T., Higashide S., Aoki M., Koga H., Satoh T., Ohashi T., Nakamura K., Katayama N., Tanaka N., Nakano M., Shigematsu N., Dokiya T., Fukushima M., Takahashi Y., Tsukiyama I., Nasu Y., Harada M., Fukagai T., Yamashita T., Matsubara A., Igawa M., Egawa S., Kakehi Y., Katsuoka Y., Kanetake H., Kubota Y., Kumon H., Yamasaki I., Suzuki K., Deguchi T., Ueno M., Naito S., Namiki M., Baba S., Hayakawa K., Hirao Y., Fujioka T., Horie S., Miki T., Murai M., Yoshida H., Itami J., Inoue T., Imai Y., Kataoka M., Kubo A., Shibuya H., Nishio M., Tanaka H., Tanaka Y., Teramukai S., Harada C., Yamashiro K., Kiba T., Kitagawa S., Uno E., Nishimura T., Kinoshita F., Iida S., Maruo S., Miyakoda K., Daimon T., Kawamoto A., Kaneda H., Yoshidomi M., Nishiyama T., Yagi Y., Namitome R., Toya K., Koike N., Yoshida K., Tabata K., Tsumura H., Kimura M., Ishiyama H., Kotani S., Kondo H., Fujimoto K., Hasegawa M., Tamamoto T., Asakawa I., Nishizawa S., Hashida I., Takezawa Y., Harada K., Tanji S., Sato K., Matsuura T., Ariga H., Ehara S., Nakamura R., Hayashi S., Ohtakara K., Kihara K., Hayashi K., Okamoto K.

International Journal of Clinical Oncology （International Journal of Clinical Oncology) 23 （ 6 ） 1148 - 1159 2018.12

ISSN 13419625

　View Summary

© 2018, Japan Society of Clinical Oncology. Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.
- Access to Document (DOI)
A Highly Advanced Gastric Cancer Maintaining a Clinical Complete Response after Chemoradiotherapy Comprising S-1 and Cisplatin

Yura M., Takahashi T., Fukuda K., Nakamura R., Wada N., Fukada J., Kawakubo H., Takeuchi H., Shigematsu N., Kitagawa Y.

Case Reports in Gastroenterology （Case Reports in Gastroenterology) 12 （ 3 ） 578 - 585 2018.09

　View Summary

© 2018 The Author(s). Published by S. Karger AG, Basel. We report a patient with highly advanced gastric carcinoma who was treated successfully with chemoradiotherapy (CRT) comprising S-1 and cisplatin. The patient was a 71-year-old male who was diagnosed with advanced gastric carcinoma by esophagogastroduodenoscopy (EGD) by medical examination. EGD demonstrated type 3 advanced gastric carcinoma in the posterior wall of the upper gastric body. An abdominal computed tomography (CT) scan showed that the gastric wall was thickened due to gastric primary tumor, and large lymph nodes (LNs) including the lesser curvature LN, anterosuperior LN along the common hepatic artery and some para-aortic LNs were detected. The patient was diagnosed with stage IV advanced gastric carcinoma according to the Japanese classification of gastric carcinoma (cT4a, cN3, cM1 [para-aortic LN], cStage IV). Preoperative CRT was carried out in an attempt to downstage the disease. Remarkable reduction of the primary tumor and metastatic LNs was observed after initial CRT, and radiological examination determined that a partial response had been achieved. Adverse effects included grade 2 anorexia and grade 3 ALP elevation (919 U/ml). No grade 4 or more severe adverse event was observed. After CRT, although we recommended curative surgery, the patient refused surgical treatment and opted for conservative treatment. Thus, we continued S-1 oral administration for 1 year. Five months after beginning CRT, upper endoscopy showed that the tumor had maintained regression and scar formation, in which no cancer cells were detected by endoscopic biopsy. The patient is doing well and has maintained a clinical complete response for more than 42 months without curative surgery. CRT could be considered as an option for treatment of patients with locally advanced gastric carcinoma diagnosed as unresectable, or for those who refuse surgical treatment.
- Access to Document (DOI)
Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

Ito Kazuto, Saito Shiro, Yorozu Atsunori, Kojima Shinsuke, Kikuchi Takashi, Higashide Satoshi, Aoki Manabu, Koga Hirofumi, Satoh Takefumi, Ohashi Toshio, Nakamura Katsumasa, Katayama Norihisa, Tanaka Nobumichi, Nakano Masahiro, Shigematsu Naoyuki, Dokiya Takushi, Fukushima Masanori, Takahashi Yutaka, Tsukiyama Iwao, Nasu Yasutomo, Harada Masaoki, Fukagai Takashi, Yamashita Takashi, Matsubara Akio, Igawa Mikio, Egawa Shin, Kakehi Yoshiyuki, Katsuoka Youji, Kanetake Hiroshi, Kubota Yoshinobu, Kumon Hiromi, Yamasaki Ichiro, Suzuki Kazuhiro, Deguchi Takashi, Ueno Munehisa, Naito Seiji, Namiki Mikio, Baba Shiro, Hayakawa Kazushige, Hirao Yoshihiko, Fujioka Tomoaki, Horie Shigeo, Miki Tsuneharu, Murai Masaru, Yoshida Hideki, Itami Jun, Inoue Toshihiko, Imai Yutaka, Kataoka Masaaki, Koike Naoyoshi

International Journal of Clinical Oncology 1 - 12 2018.06

ISSN 1341-9625

　View Summary

Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy². During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.
- Access to Document (DOI)
Influence of backscatter radiation on cranial bone fixation devices

Sakamoto Yoshiaki, Koike Naoyoshi, Takei Hideyuki, Ohno Mari, Shigematsu Naoyuki, Kishi Kazuo

Journal of Craniofacial Surgery （Journal of Craniofacial Surgery) 29 （ 4 ） 1094 - 1096 2018.06

ISSN 1049-2275

　View Summary

Postoperative radiation can cause ulcer formation, leading to the denudation of skin over alloplastic materials. The influence of backscatter radiation from fixation devices has not been investigated. The aim of this study is to evaluate backscatter dose variations for different cranial bone fixation devices in an experimental model designed to simulate postoperative radiotherapy. The authors assessed the radiation backscatter doses associated with resorbable (PLLA-PGA) and titanium plates. The samples were irradiated with 6 and 10 MV photon beams from a linear accelerator. Measurements were obtained using an ionization chamber and radiochromic films cut from the same batch. As a result, the backscatter radiation of water and PLLA-PGA proportionally decreased as the depth increased. However, the backscatter radiation of the titanium plate increased just above the plate. This depth lies in the region of the scalp. Each material showed a dose of radioactivity that was higher at 10 MV than that at 6 MV. These devices showed a significant difference, which suggested that these materials amplified the dose compared with water at 6 MV. In conclusion, it is supposed that PLLA-PGA should be used to fix the cranium to decrease the potential for radiation ulcers.
- Access to Document (DOI)
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

Kumabe A., Fukada Junichi, Kota R., Koike N., Shiraishi Y., Seki S., Yoshida K., Kitagawa Y., Shigematsu N.

Diseases of the Esophagus （Diseases of the Esophagus) 31 （ 4 ） 2018.04

ISSN 1120-8694

　View Summary

We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m² 5-fluorouracil combined with one hour infusion of 4 mg/m² cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.
- Access to Document (DOI)

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Development of new radiation sensitization therapy by drug repositioning of chloroquine

Shigematsu, Naoyuki

科学研究費補助金研究成果報告書 2020
Development of tumor-specific innovative drug Metformin for gastric cancer cell lines

Shigematsu, Naoyuki

科学研究費補助金研究成果報告書 2017
Radiosensitization in gastric cancer cell lines using different PI3K/AKT/mTOR inhibitors

Shigematsu, Naoyuki

科学研究費補助金研究成果報告書 2014
Administration of a hypoxic cell sensitizer, 6-FP, enhance of radiation-induced apoptosis in human carcinoma

Shigematsu, Naoyuki

科学研究費補助金研究成果報告書 2011
早期前立腺癌に対するヨウ素125密封小線源療法

Shigematsu, Naoyuki

Journal of the Keio Medical Society （慶應医学会) 84 （ 1 ） 1 - 8 2007.03

ISSN 03685179

Page Top ▲

Presentations 【 Display / hide 】

Dose distribution analysis of axillary lymph nodes for three-dimensional conformal radiotherapy with a field-in-field technique for breast cancer.

Ohashi T, Takeda A, Shigematsu N, Fukada J, Sanuki N, Amemiya A, Kubo A

The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) ,

2008.09
,
Poster presentation
Stereotactic body radiotherapy (SBRT) for primary lung cancer at a dose of 50Gy per 5 fractions to the periphery of the planning target volume (PTV) calculated by a superposition algorithm.

Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, Shigematsu N, Kubo A

The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) ,

2008.09
,
Poster presentation
Pleural and pericardial effusion after radiotherapy or concurrent chemo-radiotherapy (CCR) for esophageal cancer – single institutional retrospective study.

Fukada J, Shigematsu N, Kitagawa Y, Ohashi T, Kutsuki S, Kunieda E, Shiraishi Y, Kubo A, Kawase T

The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (Boston) ,

2008.09
,
Poster presentation
当院における上咽頭癌症例の検討

藤井良一、冨田俊樹、今西順久、坂本耕二、重富征爾、小川郁、茂松直之、藤井正人

第32回日本頭頚部癌学会 (東京) ,

2008.06
,
Oral presentation (general)
T1-3, N2-3の4期中咽頭癌に対するドセタキセル併用放射線療法±計画的頸部郭清術

冨田俊樹、今西順久、小澤宏之、坂本耕二、藤井良一、重富征爾、小川郁、茂松直之、深田淳一、藤井正人

第32回日本頭頚部癌学会 (東京) ,

2008.06
,
Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

クロロキンのドラッグリポジショニングによる新規放射線増感治療の開発

2018.04

-

2021.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
Development of tumor-specific innovative drug Metformin for gastric cancer cell lines

2015.04

-

2018.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Page Top ▲

Awards 【 Display / hide 】

日本医学放射線学会電子ポスター(CyPos)賞(Bronze Medal)

SHIGEMATSU NAOYUKI, 2008.04, 食道癌に対する化学放射線 / 放射線治療後の胸水、心嚢液貯留

Type of Award： Award from Japanese society, conference, symposium, etc.
日本放射線腫瘍学会ポスター発表学会賞（金賞）

SHIGEMATSU NAOYUKI, 2007.12, 前立腺シード小線源治療におけるTRUS-CT融合画像を用いた恥骨弓干渉の予測

Type of Award： Award from Japanese society, conference, symposium, etc.
日本放射線腫瘍学会優秀発表賞

SHIGEMATSU NAOYUKI, 2006.11, 前立腺シード小線源治療におけるMIRを用いた恥骨弓競合の予測

Type of Award： Award from Japanese society, conference, symposium, etc.
日本医学放射線学会優秀論文賞

Kutsuki S, Ihara N, Shigematsu N, Okamoto S, Kubo A, 2005, Relation between chromosomal aberration and radiation dose during the process of TBI

Type of Award： Award from Japanese society, conference, symposium, etc.
第1回御園生賞

Toya Kazuhito, Shigematsu Naoyuki, Itou Hisao, Yamashita Shouji, Kubo Atsushi, Kanai Tatsuaki, 1997.03, X線および重粒子線照射による培養細胞における遺伝子突然変異発生頻度の定量

Type of Award： Award from Japanese society, conference, symposium, etc.